HK1216017A1 - 二唑內酰胺 - Google Patents
二唑內酰胺Info
- Publication number
- HK1216017A1 HK1216017A1 HK16103964.8A HK16103964A HK1216017A1 HK 1216017 A1 HK1216017 A1 HK 1216017A1 HK 16103964 A HK16103964 A HK 16103964A HK 1216017 A1 HK1216017 A1 HK 1216017A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diazole
- lactams
- diazole lactams
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261734705P | 2012-12-07 | 2012-12-07 | |
US201361831700P | 2013-06-06 | 2013-06-06 | |
PCT/US2013/073692 WO2014089495A1 (en) | 2012-12-07 | 2013-12-06 | Diazole lactams |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1216017A1 true HK1216017A1 (zh) | 2016-10-07 |
Family
ID=50884047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103964.8A HK1216017A1 (zh) | 2012-12-07 | 2016-04-07 | 二唑內酰胺 |
Country Status (19)
Country | Link |
---|---|
US (3) | US9328116B2 (zh) |
EP (1) | EP2928474B1 (zh) |
JP (1) | JP6329170B2 (zh) |
KR (1) | KR102196366B1 (zh) |
CN (1) | CN104902898B (zh) |
AU (1) | AU2013355054B2 (zh) |
BR (1) | BR112015012842B1 (zh) |
CA (1) | CA2893597C (zh) |
DK (1) | DK2928474T3 (zh) |
ES (1) | ES2707323T3 (zh) |
HK (1) | HK1216017A1 (zh) |
IL (1) | IL239119A (zh) |
MX (1) | MX2015007051A (zh) |
PL (1) | PL2928474T3 (zh) |
PT (1) | PT2928474T (zh) |
RU (1) | RU2666730C2 (zh) |
SG (1) | SG11201504410PA (zh) |
WO (1) | WO2014089495A1 (zh) |
ZA (1) | ZA201504122B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2707323T3 (es) | 2012-12-07 | 2019-04-03 | Chemocentryx Inc | Diazol lactamas |
WO2014100735A2 (en) * | 2012-12-21 | 2014-06-26 | Chemocentryx, Inc. | Diazole amides |
US10544117B2 (en) | 2014-09-10 | 2020-01-28 | Temple University—Of the Commonwealth System of Higher Education | 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
EP3298004B1 (en) * | 2015-05-22 | 2021-01-06 | Biotheryx Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
EP3600289A4 (en) | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS |
MA49019A (fr) * | 2017-03-21 | 2020-02-05 | Univ Temple | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation |
KR20220034829A (ko) | 2019-07-10 | 2022-03-18 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
JPH05502179A (ja) | 1990-02-28 | 1993-04-22 | メドトロニック インコーポレーテッド | 管状器官内薬剤溶出装具 |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
DE19539091A1 (de) | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
WO1997015567A1 (de) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
US20040043904A1 (en) | 2000-09-22 | 2004-03-04 | Hiroshi Yamaguchi | N-(4-pyrazolyl) amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
GEP20074236B (en) | 2003-05-01 | 2007-11-12 | Bristol Myers Squibb Co | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
US7381714B2 (en) | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
CN101242839B (zh) | 2005-06-22 | 2012-11-07 | 凯莫森特里克斯股份有限公司 | 氮杂吲唑化合物及其制药用途 |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
FR2887450B1 (fr) | 2005-06-23 | 2007-08-24 | Rhodia Chimie Sa | Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques |
WO2007026834A1 (ja) * | 2005-09-01 | 2007-03-08 | Kumiai Chemical Industry Co., Ltd. | ピラゾール誘導体及び農園芸用除草剤 |
WO2007044885A2 (en) | 2005-10-11 | 2007-04-19 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
US20090252779A1 (en) * | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
AU2007308154A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
WO2008072724A1 (ja) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | ピラゾール誘導体 |
US7786157B2 (en) * | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
AU2008256862B2 (en) * | 2007-05-22 | 2013-01-31 | Chemocentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
CN102131828B (zh) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
DK2170309T3 (en) | 2007-06-22 | 2017-01-09 | Hydra Biosciences Inc | Dioxo-2,6, -2,3-dihydro-1H-purine compounds useful in the treatment of diseases related to activity of TRPA1 channel |
EP2221298B1 (en) * | 2007-11-13 | 2013-11-06 | Taisho Pharmaceutical Co., Ltd | Phenylpyrazole derivatives |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2297112B1 (en) | 2008-05-06 | 2013-04-03 | Boehringer Ingelheim International GmbH | Pyrazole compounds as ccr1 antagonists |
US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
CA2736362C (en) * | 2008-09-11 | 2016-10-18 | Chemocentryx, Inc. | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
JP2012508238A (ja) | 2008-11-07 | 2012-04-05 | ハー・ルンドベック・アクチエゼルスカベット | 生物活性を有するアミド |
US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
GB0915892D0 (en) | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
US9422339B2 (en) | 2012-03-29 | 2016-08-23 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
PL2855528T3 (pl) | 2012-05-31 | 2019-10-31 | Hoffmann La Roche | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi pd-1 i antagonistów vegf |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20140164267A1 (en) | 2012-12-07 | 2014-06-12 | Optionality Holdings Inc. | Compliance service |
ES2707323T3 (es) | 2012-12-07 | 2019-04-03 | Chemocentryx Inc | Diazol lactamas |
WO2014100735A2 (en) | 2012-12-21 | 2014-06-26 | Chemocentryx, Inc. | Diazole amides |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
PL3021869T3 (pl) | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
AU2014309199B2 (en) | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
LT3363790T (lt) | 2013-09-06 | 2020-05-11 | Aurigene Discovery Technologies Limited | 1,2,4-oksadiazolo dariniai, kaip imunoduliatoriai |
EP3385257A1 (en) | 2013-09-06 | 2018-10-10 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
ES2683356T3 (es) | 2013-09-06 | 2018-09-26 | Aurigene Discovery Technologies Limited | Compuestos peptidomiméticos cíclicos como inmunomoduladores |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
WO2016039749A1 (en) | 2014-09-11 | 2016-03-17 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
NZ734650A (en) | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
AU2016230795A1 (en) | 2015-03-10 | 2017-09-07 | Aurigene Discovery Technologies Limited | Therapeutic cyclic compounds as immunomodulators |
KR20170125931A (ko) | 2015-03-10 | 2017-11-15 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물 |
BR112017019304A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
CU20170120A7 (es) | 2015-03-10 | 2018-06-05 | Aurigene Discovery Tech Ltd | Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
-
2013
- 2013-12-06 ES ES13859762T patent/ES2707323T3/es active Active
- 2013-12-06 BR BR112015012842-4A patent/BR112015012842B1/pt active IP Right Grant
- 2013-12-06 RU RU2015127027A patent/RU2666730C2/ru active
- 2013-12-06 AU AU2013355054A patent/AU2013355054B2/en active Active
- 2013-12-06 PL PL13859762T patent/PL2928474T3/pl unknown
- 2013-12-06 CN CN201380064138.1A patent/CN104902898B/zh active Active
- 2013-12-06 CA CA2893597A patent/CA2893597C/en active Active
- 2013-12-06 WO PCT/US2013/073692 patent/WO2014089495A1/en active Application Filing
- 2013-12-06 KR KR1020157017980A patent/KR102196366B1/ko active IP Right Grant
- 2013-12-06 DK DK13859762.0T patent/DK2928474T3/en active
- 2013-12-06 MX MX2015007051A patent/MX2015007051A/es active IP Right Grant
- 2013-12-06 JP JP2015545891A patent/JP6329170B2/ja active Active
- 2013-12-06 US US14/099,541 patent/US9328116B2/en active Active
- 2013-12-06 SG SG11201504410PA patent/SG11201504410PA/en unknown
- 2013-12-06 PT PT13859762T patent/PT2928474T/pt unknown
- 2013-12-06 EP EP13859762.0A patent/EP2928474B1/en active Active
-
2015
- 2015-06-01 IL IL239119A patent/IL239119A/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04122A patent/ZA201504122B/en unknown
-
2016
- 2016-03-18 US US15/074,976 patent/US10744118B2/en active Active
- 2016-04-07 HK HK16103964.8A patent/HK1216017A1/zh unknown
-
2020
- 2020-07-08 US US16/923,197 patent/US11759454B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3327112T3 (en) | Agse-deficient stamme | |
EP2754580A4 (en) | DUMP TRUCK | |
DK2830816T3 (en) | Hidtil ukendt coatingkoncept | |
EP2935220A4 (en) | PERI-carbinol | |
HK1216017A1 (zh) | 二唑內酰胺 | |
HK1180931A1 (zh) | 種脈象儀 | |
GB201420527D0 (en) | Electrical-wire-protecting member | |
EP2920142A4 (en) | MÉTHANOFULLERRÈNES | |
EP2812698A4 (en) | TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR | |
EP2935227A4 (en) | DIAZOLAMIDE | |
GB2518076B (en) | Electrical-wire-protecting member | |
EP2920157A4 (en) | DI MACRO CYCLEN | |
EP2873363A4 (en) | DIOPSIMETER | |
PL2909091T3 (pl) | Ulepszone opakowanie | |
GB2500883B (en) | Improved saw-horse | |
EP2834250A4 (de) | Lithiumsilikate | |
ZA201305187B (en) | Improved brattice | |
GB201209358D0 (en) | Concept ZX | |
GB201201782D0 (en) | Con//ect | |
AU345893S (en) | Treehouse | |
GB201202887D0 (en) | TV-audio | |
GB201202916D0 (en) | E-Space | |
GB201202980D0 (en) | Stop-love | |
GB201202979D0 (en) | Ecotunnel | |
GB201202912D0 (en) | Swingdoctor |